Redhill Biopharma Ltd. income statement RDHL
In fiscal 2024, which ended Dec 31, 2024, Redhill Biopharma Ltd. reported revenue of $8.0 million, up 23.2% from the year before. It recorded a net loss of $8.3 million. The operating loss came to $14.6 million, an operating margin of -181.7%. Diluted earnings per share were $0.00. Across the 8 fiscal years shown, revenue grew from $4.0 million in fiscal 2017 to $8.0 million in fiscal 2024, about 10.5% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
|---|---|---|---|---|---|---|---|---|
| Revenue |
8
+23.2%
|
7
-89.4%
|
62
-27.9%
|
86
+33.2%
|
64
+923.0%
|
6
-24.7%
|
8
+108.6%
|
4
|
| Cost of revenue |
3
-7.7%
|
3
-89.6%
|
33
-32.5%
|
49
+33.9%
|
37
+1533.1%
|
2
-20.4%
|
3
+33.4%
|
2
|
| Gross profit |
5
+58.0%
|
3
-89.2%
|
28
-21.7%
|
36
+32.3%
|
27
+581.2%
|
4
-27.0%
|
6
+193.6%
|
2
|
| Research and development |
2
-55.0%
|
4
-51.5%
|
7
-75.3%
|
29
+78.9%
|
16
-5.3%
|
17
-29.9%
|
25
-24.6%
|
33
|
| Selling, general and administrative |
10
-41.0%
|
16
-43.3%
|
29
-11.7%
|
32
+27.5%
|
25
+121.0%
|
11
+53.0%
|
8
-6.5%
|
8
|
| Operating income |
-15
-215.7%
|
13
+129.5%
|
-43
+47.2%
|
-81
-27.4%
|
-64
-47.4%
|
-43
-9.8%
|
-39
+24.3%
|
-52
|
| Net income |
-8
-134.6%
|
24
+133.4%
|
-72
+26.7%
|
-98
-28.3%
|
-76
-80.1%
|
-42
-9.0%
|
-39
+14.8%
|
-46
|
| Basic EPS |
0.00
-100.0%
|
0.01
+108.3%
|
-0.12
+42.9%
|
-0.21
+0.0%
|
-0.21
-50.0%
|
-0.14
+17.6%
|
-0.17
+34.6%
|
-0.26
|
| Diluted EPS |
0.00
-100.0%
|
0.01
+108.3%
|
-0.12
+42.9%
|
-0.21
|
—
|
—
|
-0.17
+34.6%
|
-0.26
|
| Weighted average shares, basic |
12,323
+375.6%
|
2,591
+320.4%
|
616
+32.5%
|
465
+27.7%
|
364
+22.7%
|
297
+28.4%
|
231
+30.9%
|
177
|
| Weighted average shares, diluted |
—
|
—
|
—
|
—
|
—
|
—
|
231
+30.9%
|
177
|
| Other measures | ||||||||
| Interest coverage |
-7.11x
|
1.32x
|
-1.01x
|
-4.87x
|
-4.99x
|
-98.63x
|
-235.51x
|
-674.96x
|
| Margins | ||||||||
| Gross margin |
60.31%
|
47.03%
|
46.06%
|
42.39%
|
42.68%
|
64.09%
|
66.06%
|
46.94%
|
| Operating margin |
-181.69%
|
193.45%
|
-69.33%
|
-94.61%
|
-98.95%
|
-686.71%
|
-470.47%
|
-1,297.03%
|
| Profit margin |
-102.80%
|
366.25%
|
-115.97%
|
-113.98%
|
-118.36%
|
-672.45%
|
-464.35%
|
-1,136.61%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RDHL (Nasdaq)
- Incorporated in
- Israel
- Headquarters
- Tel Aviv, Israel
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1553846
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.